Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2022

View Archived Issues

Fgg-impaired zebrafish present dysfibrinogenemia

PDE5A targeting enhances chemotherapy efficacy in esophageal adenocarcinoma

Amylyx sponsors research at SRI on Bax and Bak inhibitors for ALS and neurodegenerative diseases

Novel orally active NLRP3 inflammasome inhibitor alleviates DSS-induced colitis in mice

Medshine Discovery patents IRAK4 and BTK inhibitors

Inventiosbio discloses new TYK2 inhibitors

Abbisko Therapeutics describes new GTPase KRAS inhibitors

Jiangsu Tasly Diyi Pharmaceutical presents new FXR agonists

Chinese researchers synthesize new vasopressin receptor antagonists

Targeting GABA-transported GAT-3 in astrocytes reduces negative outcomes of brain injury

Organoid efficacy data leads to approval of clinical trial of rare disease drug

Researchers unveil novel markers involved in pulmonary embolism

Novel HDAC3 inhibitor shows antitumor activity in 4T1-Luc xenograft mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...